Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. - Wikidata - wikimedia - TriplyDB

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

http://www.wikidata.org/entity/Q37684642

about

Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.Vasculogenic Mimicry in Prostate Cancer: The Roles of EphA2 and PI3K.Eph receptors and ephrins: therapeutic opportunities.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis.Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.

P2860

Q34029227-1A79D5EE-C7FB-43C5-971A-FF7E758E2D15 Q35691011-58B0DD45-A016-44FA-B50A-D172E76905D7 Q37015731-AEF5E8D3-70CE-42C1-9A89-18476DACB22A Q38257853-4FAD6743-F68A-481A-9566-C7123AAE7017 Q38258014-A641DA33-5EC5-47FB-BF18-DC0D8AF63D46 Q38745843-F0C7D636-40EF-4AB5-82FD-A11E4B0CFD51 Q38795257-34802046-EF9F-4B2A-8CDF-51D68AF0A25E Q47143187-B526D64C-1352-40D4-8737-0DC251F316DE Q50232638-6D10D07D-D048-4E05-85A4-689AD0B52C2A Q52751765-7D887733-34DF-47A8-B531-931563E56B6D

P2860

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

http://www.wikidata.org/entity/Q37684642

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@en

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@nl

type

label

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@en

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@nl

prefLabel

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@en

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@nl

P1433

Q37684642-068D37D1-B206-4349-B13D-821F1E1EF9DE

P1476

Q37684642-8B07EBFD-12DA-4352-BC0A-CE62C4C75BC1

P2093

Q37684642-106D3DFF-0B8F-4E5F-988C-928D9A1871B5

Q37684642-116B97BB-B292-4BAA-9947-D8621DEF55ED

Q37684642-156217F4-05EA-4070-9234-87A9C03002CE

Q37684642-23C39631-9736-4B2E-9561-FD17B1A71CE0

Q37684642-2B271E7B-6C7F-4BB4-BC33-18F82F2B9501

Q37684642-30C85C2A-F009-46AD-BF9A-3973BAE2112A

Q37684642-3A52F461-97B6-4A68-9D0B-B412CEDB286B

Q37684642-48269542-D2A8-4D4B-9775-2FC872AA387F

Q37684642-4E768194-6E59-40F0-91FA-004C9B08CD4B

Q37684642-6DD5D2A6-9244-4E51-9F2A-0A47EA40E5CB

P2860

Q37684642-03CBEC98-DDCF-41BD-A16A-0D45CEDB3EB8

Q37684642-08392588-4719-44C9-B365-1D34DAA4F18B

Q37684642-09DA6AEE-47BE-4056-8B53-5B17F3712A15

Q37684642-139FEDEA-B1BE-41F2-829D-12F301A4864B

Q37684642-18E2BE9C-56AA-4B94-BE2A-A406F3FFDAEC

Q37684642-1A8DC44A-BEFE-4ADD-BA96-8A3241D28DED

Q37684642-1D87D203-AFCD-442E-83B9-86DB8D254030

Q37684642-23CE104C-736D-478C-8699-8686CE69EB6F

Q37684642-30F87F71-9AE2-498D-A581-2067BD5FE176

Q37684642-399ADB25-38A1-470A-A6AD-D069EAFAFA49

P304

Q37684642-93BB0711-4251-4A77-82B4-9582DC84EDD4

P31

Q37684642-9B11FF34-C3FC-4DCF-9982-43BF46AB8C08

P356

Q37684642-72F3D73B-D478-412C-9B56-94C4173AD0FC

P407

Q37684642-B5785E11-22B0-4C22-8077-B6877C97EF3A

P433

Q37684642-4356A9DB-2193-4102-873F-9D36661A8136

P478

Q37684642-A5DC46DB-FDC0-4271-A497-E661EFE1B802

P50

Q37684642-92375EEC-859E-44E6-A06A-70D63A6FF2C5

P577

Q37684642-CCBBB492-EFBC-40C5-A0F7-E52E717C6A08

P698

Q37684642-EA63F09E-9DDA-4267-A1A6-7BBE6C2D63B6

P932

Q37684642-CC88E86C-A3E2-4D6F-AB68-3D87A74E49B1

P356

1078-0432.CCR-13-2141

P1433

Clinical Cancer Research

P1476

Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Behrouz Zand

http://www.w3.org/2001/XMLSchema#string

Bryan Fellman

http://www.w3.org/2001/XMLSchema#string

Chad V Pecot

http://www.w3.org/2001/XMLSchema#string

Chunhua Lu

http://www.w3.org/2001/XMLSchema#string

Diana Urbauer

http://www.w3.org/2001/XMLSchema#string

Duangmani Thanapprapasr

http://www.w3.org/2001/XMLSchema#string

Heather J Dalton

http://www.w3.org/2001/XMLSchema#string

Hee Dong Han

http://www.w3.org/2001/XMLSchema#string

Jie Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt

Integrated genomic characterization of endometrial carcinoma

Direct observation of individual endogenous protein complexes in situ by proximity ligation

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Caveolins, liquid-ordered domains, and signal transduction.

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

P304

1846-1855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-2141

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Rajesha Rupaimoole

P577

2014-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24486585

http://www.w3.org/2001/XMLSchema#string

P932

3975695

http://www.w3.org/2001/XMLSchema#string